AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39727210 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers (39 measured in TINSAL-T1DN)
Number of subjects: 525
Study 39727210 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 525
Study 39727283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 500 mg TID
Number of subjects: 32
Study 39727283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 1000 mg TID
Number of subjects: 32
Study 39727283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 1500 mg TID
Number of subjects: 32
Study 39727283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 2000 mg TID
Number of subjects: 32
Study 39727283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 39727287 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Arm Boot Camp (V-ABC)
Number of subjects: 73
Study 39727287 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (usual care)
Number of subjects: 73
Study 39727476 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride Gel
Number of subjects: 0
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic cardiovascular disease (ASCVD)
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypercholesterolemia
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal thyroid function (ATF)
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of ASCVD
Number of subjects: 7704
Study 39728301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid values
Number of subjects: 7704
Study 39728634 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39728639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care intervention (Thrive)
Number of subjects: 0
Study 39728639 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence Based Quality Improvement (EBQI) meetings
Number of subjects: 0
Study 39728639 — intervention group
Group type: EXPERIMENTAL
Intervention: Formative Evaluation (FE) research
Number of subjects: 0
Study 39729067 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term menopausal hormone therapy (mHT)
Number of subjects: 0
Study 39729067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39729067 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated systolic blood pressure (SBP)
Number of subjects: 0
Study 39729067 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated diastolic blood pressure (DBP)
Number of subjects: 0
Study 39729135 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cemented stem THA
Number of subjects: 96
Study 39729186 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (PWT)
Number of subjects: 57
Study 39729186 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 57
Study 39729347 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide-1 Receptor Agonists
Number of subjects: 0
Study 39729347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-Glucose Cotransporter 2 Inhibitors
Number of subjects: 0
Study 39729347 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl Peptidase-4 Inhibitors
Number of subjects: 0
Study 39729347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 0
Study 39729390 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMHD1 protein expression in HER2-enriched/HER2+ and basal-like (BL)/ER-/HER2- breast cancer
Number of subjects: 564
Study 39729390 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMHD1 gene expression
Number of subjects: 564
Study 39729390 — intervention group
Group type: COMPARATOR
Intervention: SAMHD1 mRNA levels in responders receiving capecitabine
Number of subjects: 564
Study 39729440 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation via rectal tube, using a preparation mixed from 7 thawed aliquots (50 mL) from fresh stool of 7 healthy unrelated donors.
Number of subjects: 36
Study 39729440 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment based on oral diosmectite.
Number of subjects: 36
Study 39729440 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation via rectal tube.
Number of subjects: 36
Study 39729499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) as first-line therapy
Number of subjects: 997
Study 39729499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) as first-line therapy
Number of subjects: 997
Study 39729499 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 997
Study 39729499 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 997
Study 39729499 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 997
Study 39729499 — intervention group
Group type: COMPARATOR
Intervention: Intensive care unit stay
Number of subjects: 997
Study 39729499 — intervention group
Group type: COMPARATOR
Intervention: Transfusion events
Number of subjects: 997
Study 39729677 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type (KRASwt) patients
Number of subjects: 378
Study 39729677 — intervention group
Group type: COMPARATOR
Intervention: KRAS mutated (KRASm) patients
Number of subjects: 378
Study 39729677 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 378
Study 39729677 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumors
Number of subjects: 378
Study 39729677 — intervention group
Group type: COMPARATOR
Intervention: KRAS mutated tumors
Number of subjects: 378
Study 39729677 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type PDAC
Number of subjects: 378
Study 39729677 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients considered eligible for early-phase trials
Number of subjects: 378
Study 39729682 — intervention group
Group type: EXPERIMENTAL
Intervention: HET score
Number of subjects: 1460
Study 39729682 — intervention group
Group type: COMPARATOR
Intervention: HEART score
Number of subjects: 1460
Study 39729872 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove intervention
Number of subjects: 3200
Study 39729872 — intervention group
Group type: COMPARATOR
Intervention: Exposure-response analysis with BC
Number of subjects: 3200
Study 39730000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist)
Number of subjects: 15
Study 39730001 — intervention group
Group type: EXPERIMENTAL
Intervention: GPH (gemcitabine, paricalcitol, hydroxychloroquine)
Number of subjects: 0
Study 39730078 — intervention group
Group type: EXPERIMENTAL
Intervention: digital cognitive behavioral therapy for insomnia (dCBT-I)
Number of subjects: 300
Study 39730078 — intervention group
Group type: COMPARATOR
Intervention: patient education control program
Number of subjects: 300
Study 39730154 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal foot length (FL) measurement cutoff of ≤7.6 cm
Number of subjects: 336
Study 39730154 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot length measurement
Number of subjects: 336
Study 39730154 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot length cutoff of ≤7.6 cm
Number of subjects: 336
Study 39730154 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal FL measurement
Number of subjects: 336
Study 39730195 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth in NICU
Number of subjects: 18847
Study 39730195 — intervention group
Group type: COMPARATOR
Intervention: Birth in LNU
Number of subjects: 18847
Study 39730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative electroencephalogram (qEEG)
Number of subjects: 60
Study 39730694 — intervention group
Group type: COMPARATOR
Intervention: Non-delirium group (control)
Number of subjects: 60
Study 39730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium group
Number of subjects: 60
Study 39730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak value of F3-P3 derivation
Number of subjects: 60
Study 39730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, APACHE II scores, lactate, hospital days
Number of subjects: 60
Study 39731054 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of HIV teams with trained GP ambassadors and expert-led education for GPs (phase 1) and peer-to-peer case feedback (phase 2).
Number of subjects: 132338
Study 39731054 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of HIV teams (phase 1 and phase 2).
Number of subjects: 132338
Study 39731054 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of HIV teams.
Number of subjects: 132338
Study 39731056 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based emotion regulation intervention
Number of subjects: 20
Study 39731060 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula containing Bifidobacterium animalis ssp. lactis CP-9
Number of subjects: 180
Study 39731060 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula containing Lactobacillus salivarius AP-32
Number of subjects: 180
Study 39731060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 180
Study 39731098 — intervention group
Group type: EXPERIMENTAL
Intervention: iPeer2Peer program (peer mentoring through up to ten 30-min video calls over a 15-week period)
Number of subjects: 164
Study 39731098 — intervention group
Group type: EXPERIMENTAL
Intervention: iPeer2Peer program
Number of subjects: 164
Study 39731098 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 164
Study 39731129 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 2365
Study 39731129 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2365
Study 39731298 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) plus methylene blue tracing for sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC)
Number of subjects: 156
Study 39731636 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch (SE) mode
Number of subjects: 25
Study 39731636 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective-enamel-etching (SLE) mode
Number of subjects: 25
Study 39731636 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (ER) mode
Number of subjects: 25
Study 39731853 — intervention group
Group type: EXPERIMENTAL
Intervention: MASH patients undergoing bariatric surgery
Number of subjects: 100
Study 39731908 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive Treg therapy
Number of subjects: 10
Study 39731908 — intervention group
Group type: COMPARATOR
Intervention: Control reference group
Number of subjects: 10
Study 39731909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ; 600 mg, bid) plus palbociclib (200 mg, qd)
Number of subjects: 29
Study 39732356 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED (2 weeks of EEN followed by CDED+PEN)
Number of subjects: 56
Study 39732356 — intervention group
Group type: COMPARATOR
Intervention: EEN (8 weeks of EEN followed by PEN with free diet)
Number of subjects: 56
Study 39732356 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED
Number of subjects: 56
Study 39732356 — intervention group
Group type: COMPARATOR
Intervention: EEN
Number of subjects: 56
Study 39732365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib (2 cycles of 28 days) followed by surgical resection and 3 years of adjuvant osimertinib
Number of subjects: 25
Study 39732365 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib
Number of subjects: 25
Study 39732398 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (15g) before breakfast, water before lunch and dinner
Number of subjects: 21
Study 39732398 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (15g) before breakfast and WPI (10g) before lunch and dinner
Number of subjects: 21
Study 39732398 — intervention group
Group type: COMPARATOR
Intervention: Control (water before meals)
Number of subjects: 21
Study 39732437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (10-day controlled)
Number of subjects: 34
Study 39732437 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet (10-day controlled, 60% animal protein)
Number of subjects: 34
Study 39732437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 34
Study 39732437 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 34
Study 39732438 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (20g)
Number of subjects: 17
Study 39732438 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided doses of inulin (20g in 62.5mL every 45 minutes over 6 hours)
Number of subjects: 17
Study 39732438 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (20g)
Number of subjects: 17
Study 39732474 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive home visits by community health workers (CHWs)
Number of subjects: 137
Study 39732474 — intervention group
Group type: COMPARATOR
Intervention: Fixed-site CHW care
Number of subjects: 137
Study 39732483 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional remission group (patients who achieved functional remission after antipsychotic discontinuation)
Number of subjects: 480
Study 39732483 — intervention group
Group type: COMPARATOR
Intervention: Functional non-remission group (patients who did not achieve functional remission after antipsychotic discontinuation)
Number of subjects: 480
Study 39732493 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous vaginal birth
Number of subjects: 897
Study 39732493 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental vaginal birth (IVB)
Number of subjects: 897
Study 39732493 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 897
Study 39732493 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of care
Number of subjects: 897
Study 39732649 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly self-collected oral swabs (OS)
Number of subjects: 1570
Study 39732649 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly self-collected oral-nasal swab (ONS)
Number of subjects: 1570
Study 39732649 — intervention group
Group type: COMPARATOR
Intervention: Nurse collected nasopharyngeal swab (NPS)
Number of subjects: 1570
Study 39732649 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence and acceptability of ONS and OS
Number of subjects: 1570
Study 39732649 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic only SARS-CoV-2 testing arm
Number of subjects: 1570
Study 39732657 — intervention group
Group type: EXPERIMENTAL
Intervention: SARC-F questionnaire
Number of subjects: 2455
Study 39732657 — intervention group
Group type: EXPERIMENTAL
Intervention: SARC-CalF questionnaire
Number of subjects: 2455
Study 39732657 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf circumference
Number of subjects: 2455
Study 39732696 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH/LMWH + 20 mg rtPA/6 h intravenously
Number of subjects: 210
Study 39732696 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH + 20 mg rtPA/6 h via USAT
Number of subjects: 210
Study 39732696 — intervention group
Group type: COMPARATOR
Intervention: UFH/LMWH
Number of subjects: 210
Study 39732701 — intervention group
Group type: EXPERIMENTAL
Intervention: mSoCIAL (modified Social Cognition Individualized Activity Lab), 10 weekly sessions
Number of subjects: 40
Study 39732701 — intervention group
Group type: EXPERIMENTAL
Intervention: mSoCIAL (modified Social Cognition Individualized Activity Lab)
Number of subjects: 40
Study 39732701 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study 39732703 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg AYP-101
Number of subjects: 26
Study 39732703 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg AYP-101
Number of subjects: 26
Study 39732703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 39732716 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA nasal swab PCR testing in addition to usual care
Number of subjects: 0
Study 39732716 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pain experienced during labor
Number of subjects: 813
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education level
Number of subjects: 813
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Having diabetes
Number of subjects: 813
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of obstetric complications
Number of subjects: 813
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial rupture of membrane (ARM) and oxytocin induction
Number of subjects: 813
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower age
Number of subjects: 813
Study 39732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher A-LPQ birth pain score
Number of subjects: 813
Study 39733245 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine-based POC metric of PrEP adherence counseling
Number of subjects: 46
Study 39733245 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care counseling
Number of subjects: 46
Study 39733282 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pudendal nerve blockade
Number of subjects: 104
Study 39733282 — intervention group
Group type: COMPARATOR
Intervention: Bilateral normal saline pudendal injections
Number of subjects: 104
Study 39733282 — intervention group
Group type: COMPARATOR
Intervention: No pudendal injection
Number of subjects: 104
Study 39733294 — intervention group
Group type: EXPERIMENTAL
Intervention: p-DCR-FFP (250 mL)
Number of subjects: 10
Study 39733294 — intervention group
Group type: COMPARATOR
Intervention: p-DCR-normal saline
Number of subjects: 10
Study 39733457 — intervention group
Group type: EXPERIMENTAL
Intervention: AVIAR 2.0 system for robot-assisted PCI
Number of subjects: 20
Study 39733460 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 1586
Study 39733934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 16
Study 39734047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprifermin 100 μg every 6 months (Q6M)
Number of subjects: 549
Study 39734047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprifermin 100 μg every 12 months (Q12M)
Number of subjects: 549
Study 39734047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprifermin 30 μg every 6 months (Q6M)
Number of subjects: 549
Study 39734047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprifermin 30 μg every 12 months (Q12M)
Number of subjects: 549
Study 39734047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 39734047 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom progressors
Number of subjects: 549
Study 39734195 — intervention group
Group type: EXPERIMENTAL
Intervention: ReAces occluder
Number of subjects: 30
Study 39734195 — intervention group
Group type: COMPARATOR
Intervention: Traditional occluders
Number of subjects: 30
Study 39734604 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular Functional Exercises
Number of subjects: 0
Study 39734604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Isometric Exercises
Number of subjects: 0
Study 39734604 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39734708 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA-directed CAR T therapy
Number of subjects: 2
Study 39734708 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids combined with vedolizumab
Number of subjects: 2
Study 39734743 — intervention group
Group type: EXPERIMENTAL
Intervention: Various agents including decitabine, cytarabine, daunorubicin, etoposide, venetoclax, and two experimental bromodomain and extraterminal (BET) inhibitors
Number of subjects: 1
Study 39735169 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis response planning (CRP)
Number of subjects: 0
Study 39735169 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 39735351 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) 2.0 mg b.i.d. (BOS-BOS)
Number of subjects: 48
Study 39735351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BOS-PBO)
Number of subjects: 48
Study 39735403 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 22
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab (CD3 monoclonal antibody)
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab (anti-CD3 monoclonal antibody)
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (anti-CD25 monoclonal antibody)
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladarixin (CXCR1/2 inhibitor)
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 0
Study 39735417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lantidra
Number of subjects: 0